Status:
COMPLETED
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
Lead Sponsor:
UCB Pharma
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 \[NCT00308581\...
Eligibility Criteria
Inclusion
- Patients having completed study C87042 \[NCT00308581\] (previously treated with infliximab)
Exclusion
- Subject withdraw from C87042 \[NCT00308581\] study
- Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 \[NCT00308581\] study
- Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment
- Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT00333788
Start Date
October 1 2006
End Date
April 1 2010
Last Update
August 7 2018
Active Locations (65)
Enter a location and click search to find clinical trials sorted by distance.
1
Gainesville, Florida, United States
2
Atlanta, Georgia, United States
3
Chicago, Illinois, United States
4
Indianapolis, Indiana, United States